BofA downgraded Exelixis (EXEL) to Underperform from Neutral with a price target of $41, down from $43, citing valuation and limited high-impact catalysts seen in 2026. The company has limited patent life on Cabometyx with loss of exclusivity by 2031 and has yet to de-risk meaningful peak sales for a follow-on asset, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Klaviyo, Wingstop among Stephens Best Ideas for 2026
- Exelixis and Merck Advance LITESPARK-033: A New Kidney Cancer Combo With High-Stakes Market Potential
- Exelixis’s Strategic Oncology Expansion and Pipeline Innovations Justify Buy Rating
- Exelixis to host research and development day
- Exelixis’s Oncology Potential: A Buy Rating Amid Evolving mCRC Treatment Landscape and Unmet Needs